Aims Left ventricular hypertrophy has been shown to be an independent predictor of cardiovascular morbidity. Acknowledging the skewed distribution of left ventricular mass, we wanted to develop criteria for left ventricular hypertrophy based on percentiles of left ventricular mass, and observe the effect on estimates of left ventricular hypertrophy prevalences in different subgroups and on the relationship to cardiovascular risk factors in a general population.
Introduction
Left ventricular hypertrophy has been associated both with hypertension and increased cardiovascular morbidity and mortality [1] . Hypertrophy is commonly considered a physiological response to the increased workload imposed by risk factors of cardiovascular disease [2] . This view of left ventricular hypertrophy, as a marker of exposure to other cardiovascular risk factors, has recently been contradicted by studies showing a decreased risk of cardiovascular events following reduction in left ventricular hypertrophy, independent of reductions in other cardiovascular risk factors [3, 4] .
Calculations of left ventricular mass with M-mode echocardiography was early established as a valid non-invasive measure of hypertrophy verified by autopsy [5, 6] . Despite the development of new diagnostic methods, M-mode echocardiography is still the method of choice in epidemiological surveys [7] . The criteria for left ventricular hypertrophy have been established from samples, from which individuals exceeding the upper normal limits of the main predictors of left ventricular mass have been excluded. These predictors have been body mass index, systolic blood pressure, cardiovascular disease, antihypertensive medication and valvular heart disease. Previous analysis of left ventricular hypertrophy suffers from two methodological limitations. First, most studies have ignored the fact that the distribution of left ventricular mass is skewed even in 'healthy' reference samples, and have accordingly used the mean left ventricular mass +2 SD as the upper limit. If the skewed distribution is not caused by pathology, this would cause lower reference limits, and consequently an overestimation of left ventricular hypertrophy prevalence. Secondly, since the prevalence of hypertension increases by age, a large number of elderly have been excluded from the reference samples. This has reduced the generalizability of the currently used left ventricular hypertrophy criteria.
Most population-based echocardiographic data on left ventricular hypertrophy are based on the Framingham study. Since both the incidence of cardiovascular disease and the cardiovascular risk factor levels varies over time and space, there is a need for a validation of these results in a new population, using the ultrasound technology and analytical methods available today.
In a large sample of 2794 men and women with a high mean age, we wanted to establish new sex-and age-specific percentile-derived criteria for left ventricular hypertrophy-based M-mode echocardiography. Our sample was randomly selected from a screening of the general population where possible cardiovascular risk factors were recorded by questionnaire and general examination. Thereby we could elucidate the prevalence and predictors of left ventricular hypertrophy. The relative importance of the main modifiable predictors of left ventricular hypertrophy, body mass index and systolic blood pressure in each gender, was assessed.
Material and methods

Study population
The Tromsø Study was started in 1974 and is a prospective follow-up study of the municipality of Tromsø, Norway. The main focus has been on the epidemiology of cardiovascular disease. The study design includes repeated population health surveys to which selected birth cohorts and random samples of other cohorts were invited. The previous surveys were conducted in 1974, 1979 and 1986 [8] [9] [10] [11] [12] . The fourth survey started in September 1994 and was completed in September 1995. A total of 27 159 subjects older than 24 years, 77% of the eligible population, attended the first visit. A protocol similar to that of the previous surveys and to the Norwegian Counties Study was followed [8] [9] [10] [11] [12] . The examination included standardized measurements of blood pressure, weight, height, and non-fasting serum lipids. Two self-administered questionnaires, checked by trained nurses, covered previous and present diseases and symptoms, use of drugs, smoking, alcohol intake and physical activity. All subjects aged 55-74 and random 5-10% samples of the other age groups were invited to a second visit for more extensive screening. A total of 6891 subjects attended the second visit, 98% of those who participated in the first visit. Because of high attendancy rates at the first visit in these age groups, the second visit comprised 88% of those initially invited. These subjects had been alternately allocated by computer to one of two lines of examination when attending the first visit. Due to lack of capacity, only 3287 subjects on one line were examined by echocardiography. These 3287 did not differ from the total sample attending the second screening in baseline characteristics. 2794 (85%) had M-mode registrations of good quality, making left ventricular mass calculations possible.
Echocardiography
All subjects were examined by medical doctors, (2362 subjects by one doctor, the remaining 432 by two expert cardiologists), using a VingMed CFM 750 (VingMed Sound A/S, Horten, Norway). The subjects were examined in a supine, left lateral position with a combined 3·25 MHz mechanical and 2·5 MHz Doppler probe. The echocardiographic examinations were performed using the standard apical and parasternal long and shortaxis views. Left ventricular diastolic dimensions were measured from standard two-dimensional guided M-mode registrations according to the leading edge to leading edge convention [13] , using EchoPAC software. Only one heart cycle was measured per subject.
Left ventricular mass was calculated using the correction of the cube formula proposed by Devereux et al. for leading edge to leading edge measurements [14] :
The presence of valvular heart disease was evaluated by two dimensional colour Doppler for mitral insufficiency, colour M-mode for aortic insufficiency and pulsed wave Doppler for mitral and aortic stenosis. The presence of other cardiac abnormalities was noted.
Reproducibility
In a subsample of 49 subjects, a reproducibility study was performed by the two main observers. Both observers examined all subjects twice with the measurements done on line. For the two observers the mean SD intraobserver difference in left ventricular mass (one week interval) was 3·0 39·0 g and 7·0 25·5 g, respectively. The inter-observer difference in left ventricular mass (no time interval) was 14·8 32·5 g. There was no difference in baseline characteristics for subjects examined by each observer. Left ventricular mass was indexed by height to allow for the increase of left ventricular mass with increasing height, without masking the increase in left ventricular mass with increasing body mass index [15] .
Self-reported risk factors
A history of cardiovascular disease was confirmed if one or more of the following items were reported; myocardial infarction, angina or stroke. Units of alcohol consumption per fortnight is a sum of self-reported intake of glasses of wine, beer or liquor over 14 days. Strenuous leisure time physical activity was graded according to hours of exercise resulting in sweating or breathlessness during an average week.
Reference sample
A reference sample of 954 subjects had the following characteristics: a systolic blood pressure of less than 140 mmHg and a diastolic blood pressure of less than 90 mmHg at the echocardiographic screening; no antihypertensive medication; no cardiopulmonary disease or history of diabetes; weight no more than 20% above or below the Norwegian middle weight by height tables [16] ; and no evidence of valve disease by echocardiography (mitral regurgitant area less than 4 cm 2 , diameter of aortic regurgitant jet less than 30% of outflow tract diameter and aortic outflow gradient less than 30 mmHg). These criteria excluded 29% of those younger than 40, gradually rising to 87% in those 70 years or older. The weight and hypertension criteria caused 89·7% of exclusions and cardiopulmonary diseases 8·3%. The remaining were excluded due to valvular heart disease.
Statistics
To contrast differences between groups, analysis of covariance were used in the general linear model procedure in the SAS statistical package [17] . Means and prevalences were adjusted for age. The aim was to define left ventricular hypertrophy criteria by estimating sexspecific 97·5 percentile values for left ventricular mass by height for each age group 25-39, 40-44, 45-54, 55-59, 60-64, 65-69 and >69 years. This was done both in the total and reference samples. Any effect of age on left ventricular mass by height percentiles was tested in a weighted linear regression model, the weight being the number of subjects in each age group. Left ventricular hypertrophy criteria were chosen as the sex-specific 97·5 percentiles from the reference sample.
A general association between left ventricular hypertrophy prevalence and single variables was tested with age-and sex-adjusted logistic regression analysis for each variable. The multivariate association was tested with age and all other variables significant in at least one gender. Any gender difference in odds ratios were tested with gender and all gender interaction terms in the full model. The main predictors of left ventricular mass, body mass index and systolic blood pressure were divided in quintiles to assess whether an association was caused by outliers or showed a linear relationship with left ventricular hypertrophy over the whole distribution. For body mass index, the quintile limits were as follows: <22·3, 22·3-24·2, 24·3-26·1, 26·2-28·8 and >28·8 kg . m 2 for men and <23·5, 23·5-25·1, 25·2-26·5, 26·6-28·6 and >28·6 kg . m 2 for women. Cut-off levels for systolic blood pressure quintiles were <124, 124-132, 132·5-141, 141·5-155, >155 and <120, 120-129, 129·5-141, 141·5-156·5, >156·5 mmHg, for men and women, respectively. To simplify an evaluation of body mass index independent of systolic blood pressure, age-adjusted prevalences of left ventricular hypertrophy for quintiles of body mass index were estimated in three strata of systolic blood pressure according to the WHO criteria for hypertension [18] . Two strata of systolic blood pressure were entered in the logistic regression model as indicator variables. The middle stratum was regarded as the reference. A two sided value of P<0·05 assessed statistical significance.
Results
The characteristics of the total population and the reference sample are summarized in Table 1 . Of the total population, 28·9% were more than 20% over, and 1·3% more than 20% below Norwegian midweight tables (no significant gender difference). A history of cardiovascular disease was reported in 15·6% of men and 9·9% of women. The prevalence of hypertension according to WHO criteria (systolic >140 or diastolic >90 or being on antihypertensive medication) was 48·1% and 47·7%, for men and women, respectively (data not shown). The reference sample was leaner, younger, had a higher high density lipoprotein cholesterol level (women only) and a higher prevalence of smoking than the total population. The prevalence of valvular heart disease was 4·7% in men and 6·7% in women.
In Fig. 1 the percentiles of left ventricular mass by height are plotted for each age group. As shown, there was little overall increase in left ventricular mass associated with age in the reference sample. Age affected the upper 10% of the population only, although not significantly (Pd0·07). In the total sample, there was an increasing effect of age from the 50th percentile and upwards. There were two striking gender differences: first, that each percentile was significantly lower in women; second, there was a difference in the relationship between the 97·5 percentile of the total sample and the reference sample. In men, the 97·5 percentile of the total sample was higher than that of the reference sample in all age groups. However, for women the curves were almost identical up to the age of 65, indicating that the allowance for hypertension, a history of cardiovascular disease and obesity in the total sample had a stronger impact on the upper percentiles in men. The increase in left ventricular mass by height for women in the total sample started around the mean age for menopause in our material (48·5 4·9 years).
Since there was no significant prediction by age in the reference sample of the 97·5 percentile, for either sex, the percentile for left ventricular mass by height was estimated for the whole reference sample and was
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145·5 g . m 1 for men and 125·4 g . m 1 for women. When these reference values were applied on the total population, the prevalences of left ventricular hypertrophy were 14·9% for men and 9·1% for women ( Table 2 ). The age-adjusted prevalences of left ventricular hypertrophy were significantly higher in subjects who reported myocardial infarction, angina, antihypertensive medication or who had valvular heart disease diagnosed, than in those without cardiovascular disease. There was a substantial increase in left ventricular hypertrophy prevalence over groups with stroke, angina alone or myocardial infarction with or without angina in men, but not in women (chi-squared for trend P<0·001 for men and 0·40 for women, not shown in table). An independent association between valvular heart disease, antihypertensive medication, cardiovascular disease and left ventricular hypertrophy is suggested. Among those with a history of cardiovascular disease, the increasing prevalence of left ventricular increased as more of these criteria were fulfilled (P for trend <0·02 for both sexes, not shown in table). Similarly, users of antihypertensive medication with valvular heart disease had a significantly higher prevalence of left ventricular hypertrophy than those without. The use of antihypertensive medication gave a prevalence of left ventricular hypertrophy similar to that of valvular heart disease alone and of cardiovascular disease alone.
The independent predictors of left ventricular hypertrophy by multivariate logistic regression were age, male gender, body mass index, valvular heart disease, systolic blood pressure, a history of cardiovascular disease and the use of antihypertensive medication (Table 3 ). The presence of valvular heart disease gave the highest risk, with an odds ratios for left ventricular hypertrophy of 4·19 (95% CI 2·79-6·30). Body mass index was, as shown by a Wald chi-square score of 107·9, the most important variable for categorizing subjects as having left ventricular hypertrophy. The odds ratio for left ventricular hypertrophy was 1·96 (1·72-2·22) for an increase in body mass index of 3·8 kg . m 2 (1 SD). The odds ratio for systolic blood pressure was 1·46 (1·29-1·69) for an 20·8 (1 SD) mmHg increase. Units of alcohol consumption, serum cholesterol, daily smoking, physical activity, waist/hip ratio and a history of diabetes were left out of the final model since they did not cause a significant change in the maximal likelihood estimate. There was no significant gender difference in odds ratio for any of the variables entered in the model.
In order to assess the relative contribution of the potentially modifiable risk factors, we stratified body mass index and systolic blood pressure. Since subjects with a history of cardiovascular disease could have increased their left ventricular mass as a consequence of cardiovascular disease as well as of their risk factor level, these subjects were excluded from the analysis. As shown in Fig. 2 , there was a parallel, gradual and significant increase in left ventricular hypertrophy prevalences for increasing quintiles of body mass index, with women lower at all levels, (P<0·0001, not shown in Fig. 2) . The increasing gender difference in left ventricular hypertrophy prevalence over increasing systolic blood pressure quintiles was non significant, (P=0·16, not shown in Fig. 2) . In order to investigate any 
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intercorrelation between body mass index and systolic blood pressure (r=0·16 for men and 0·33 for women), the two variables were stratified in the same analysis (Fig. 3) . In both men and women there was a significant association between left ventricular hypertrophy and systolic blood pressure. For women this was evident in the presence of high pressure only; the threshold above 159 mmHg was significant with an odds ratio for left ventricular hypertrophy of 2·13 (1·32-3·44) compared with the lower systolic blood pressure (no statistical results shown in figure) . Body mass index was, however, a significant predictor in all three blood pressure strata in women. For men, all three blood pressure strata were significantly different and the prevalence of left ventricular hypertrophy had a consistently steeper increase over body mass index quintiles with increasing blood pressure levels. The odds ratios for left ventricular hypertrophy of increasing systolic blood pressure strata were 1·86 (1·17-2·98) and 4·92 (3·03-7·98) compared with the lowest stratum. In these subjects without a history of cardiovascular disease, the multivariate odds ratios for left ventricular hypertrophy for 1 SD change in systolic blood pressure were 1·87 (1·54-2·28) in men, vs 1·26 (0·99-1·61) in women. This gender difference in the independent odds ratios was the only significant gender difference in this subgroup (P=0·003, all interaction terms with gender entered in the same model). 
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Discussion
In this general population, 15% of men and 9% of women were found to have left ventricular hypertrophy as defined by M-mode derived percentile criteria. The main predictors of left ventricular hypertrophy in our study of 2794 subjects were age, male gender, body mass index, valvular heart disease, systolic blood pressure, a history of cardiovascular disease and present use of antihypertensive medication. The most important variable for categorizing subjects as having left ventricular hypertrophy was body mass index. Weight reduction to treat left ventricular hypertrophy has previously been documented either as more, or as potent as antihypertensive treatment in selected groups of patients [19, 20] . The finding of a gradually increasing prevalence of left ventricular hypertrophy over the whole distribution of body mass index may thus have clinical implications for a substantial part of the population.
The hypothesis of a possible synergistic association between body mass index and systolic blood pressure with left ventricular hypertrophy have seldom been a focus of population-based studies, and have only been described in one large group of hypertensive men [21] [22] [23] [24] [25] . Our population-based study supports this hypothesis, and is the first to indicate that this synergism is gender specific.
The population-based approach and the high participation rate reduce selection bias and strengthen the external validity of our results. The validity of M-mode echocardiography in estimating left ventricular mass has been well documented. Accordingly, the correlations between M-mode estimated and autopsy determined left ventricular mass range from 0·81 to 0·96 [5, 6] . The possible error introduced by the few subjects with asymmetrical ventricles after myocardial infarction who attend a population screening, will not affect our reference limits, or the prediction of left ventricular hypertrophy in subjects without a history of cardiovascular disease. No systematic intra-observer bias was evident. Moreover, the inter-observer bias was of minor importance for the internal validity of our results, since 85% of the measurements were done by one observer. Our interand intra-observer variability was slightly higher than the reader variability and the observer variability reported in other studies [26] [27] [28] . This indicates that basing our estimates on only one heart cycle only has had little effect on the variability of the M-mode measurements. Due to the potential bias introduced by inter-observer variability, the use of percentile derived criteria from our population assures a more accurate categorization than if external criteria had been used.
In order to ensure a clinically relevant risk for subsequent disease or death for the patient diagnosed with left ventricular hypertrophy, criteria should preferably be based on hard end-points from prospective follow-up studies. In the absence of such end-points in this population, the choice of criteria from a reference sample, in which subjects with cardiovascular disease or left ventricular hypertrophy risk factor levels exceeding upper normal limits have been excluded, seems preferable. Most of the exclusions from the reference sample were due to hypertension and obesity. These predictors of left ventricular hypertrophy are also important risk factors for cardiovascular disease [29] [30] [31] , and modification of both risk factors cause a reduction in left ventricular hypertrophy [19, 26] . In earlier Framingham studies, mean left ventricular mass by height +2 SD was used as left ventricular hypertrophy criteria. With these criteria they found a left ventricular hypertrophy prevalence of 16% for men and 19% for women [15] . Exchanging our percentile derived left ventricular hypertrophy criteria with criteria based on means +2 SD, our sex-specific prevalences would have increased from 14·9 to 15·1% for men and from 9·1 to 15·4% for women. We consider the use of percentiles in a general population as more meaningful, and the ensuing result is also more in accordance with known incidences of heart disease in men and women [32] . Similarly to us, Vasan et al. recently reanalysed the Framingham data using sex-specific percentiles from a healthy reference sample [33] . They acknowledge that when a continuous risk factor is dichotomized, possible information about a gradually increasing risk is lost. They showed that the relative risk of meeting hard end-points gradually increased as left ventricular mass increased above the upper normal limits for left ventricular mass by height. Women had a lower absolute risk at all levels. They confirm their previous report that left ventricular hypertrophy is more prevalent among women than men (28 vs 23%).
The fact that we, when defining our reference sample, used criteria similar to those of the Framingham Study, suggests a true population difference with regard to left ventricular hypertrophy development. Our population differed from the Framingham study in having a higher prevalence of hypertension (48% compared to 37%) and in being older (59·2 10·6 vs 50·8 years). 
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hypertrophy compared to the population in a Nordic country. Another difference with potential importance for left ventricular hypertrophy development is the substantially higher level of alcohol consumption in Framingham, especially among women [34] . As in the Framingham study [35] , we observed no association between age and left ventricular mass in a reference sample. However, in the multivariate analysis of main predictors for left ventricular hypertrophy, age was a weak independent predictor of left ventricular hypertrophy. If subjects with a history of cardiovascular disease were excluded from the multivariate analysis, age is no longer significant, indicating that the importance of age in left ventricular hypertrophy development is due either to changes imposed by cardiovascular disease or by increasing levels of risk factors common both for left ventricular hypertrophy and cardiovascular disease.
There was a significant gender difference in the importance of systolic blood pressure in predicting left ventricular hypertrophy. For women, the additive effect of systolic blood pressure to that of body mass index was only apparent above 159 mmHg, and less so than in men. For men, there was a gradually increasing prevalence of left ventricular hypertrophy with increasing systolic blood pressure levels at all levels of body mass index, indicating a strong synergistic association. Thus, for women there was little additional information obtained from taking systolic blood pressure into account. Because of the low intercorrelation of these predictors, this could imply a partial 'protection' of the effect of systolic blood pressure on left ventricular hypertrophy induction in women.
Of the few studies addressing the relative importance of body mass index and systolic blood pressure in the development of left ventricular hypertrophy, only Gottdiener et al., who found a synergistic association in hypertensive men, assess hypertrophy over increasing levels of body mass index [25] . The other studies dichotomize body mass index and have few or no hypertensive subjects [22] [23] [24] . The hypertensive reveals a gender difference in left ventricular hypertrophy prevalence.
No explanation of the observed gender difference in left ventricular hypertrophy prevalences is derived from our cross sectional study. Changes in body mass index have been shown to be the most important determinants of hypertension [36] [37] [38] . A gender difference in the response to weight change, as indicated in the study by Kuller et al. [37] could be a possible explanation for the sex-specific synergism of body mass index, systolic blood pressure and prevalence of left ventricular hypertrophy in our study. 
Conclusions
This study provides new data and analysis of echocardiographically measured left ventricular hypertrophy in a large general population. The observations support the existence of a gender difference in the relationship between body mass index, systolic blood pressure and left ventricular hypertrophy prevalence. Criteria for left ventricular hypertrophy, which may be used both in clinical practice and in research, are proposed. The strong influence of body mass index on the prevalence of left ventricular hypertrophy may contain a lesson in prevention. Based on these results, further prospective population-based studies addressing the interaction between obesity, weight reduction, left ventricular hypertrophy, hypertension and its medical treatment seem warranted.
